|
|
|
 |
FDA Approval Activities for this Drug…
Atacand HCT (candesartan cilexetil - hydrochlorothiazide) Tablets, 16-12.5 and 32-12.5 mg, AstraZeneca LP NDA 21-093 9/5/00 9/11/00 9/11/00 7/30/01 | Atacand (candesartan cilexetil), Tablets, 4, 8, 16, and 32 mg, AstraZeneca LP NDA 20-838/S019 4/23/03 | Atacand (candesartan cilexetil), Tablets, 4, 8, 16, and 32 mg, AstraZeneca LP NDA 20-838/S017 1/22/03 1/27/03 | Atacand (candesartan cilexetil), Tablets, 4, 8, 16, and 32 mg AstraZeneca LP NDA 20-838/S015 9/13/02 9/20/02 9/17/02 2/4/03 | Atacand (candesartan cilexetil), Tablets, 4, 8, 16, and 32 mg AstraZeneca LP NDA 20-838/S008 6/14/00 6/6/01 | Atacand (candesartan cilexetil) Tablets, 4, 8, 16, and 32 mg Astra Merck NDA 20-838 6/4/98 6/8/98 6/8/98 4/11/02 | Atacand Indication: for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. | Atacand (candesartan cilexetil) Tablets, AstraZeneca, Labeling Revision | | Atacand (candesartan cilexetil) Tablets, AstraZeneca, Labeling Revision | Atacand (candesartan cilexetil) Tablets, AstraZeneca, New or Modified Indication | Atacand (candesartan cilexetil) Tablets, AstraZeneca, New or Modified Indication | Atacand HCT (candesartan cilexetil and hydrochlorothiazide) Tablets, AstraZeneca, Labeling Revision | Atacand HCT (candesartan cilexetil) Tablets, AstraZeneca, Labeling Revision | ATACAND HCT (candesartan cilexetil and hydrochlorothiazide) Tablets, AstraZeneca LP, Formulation Revision | Atacand (candesartan cilexetil) Tablets, AstraZeneca, Efficacy Supplement with Clinical Data to Support | Atacand HCT (candesartan cilexitil and hydrochlorothiazide) Tablets, AstraZeneca, Labeling Revision | Atacand HCT (candesartan and cilexetil hydrochlorothiazide) Tablets, AstraZeneca, Labeling Revision | Atacand (candesartan cilexetil) Tablets, AstraZeneca LP, Labeling Revision | Candesartan Cilexetil and Hydrochlorothiazide Tablets, Matrix Laboratories Ltd., Tentative Approval | Candesartan Cilexetil, candesartan cilexetil, Tablet; Oral, Matrix Labs Ltd, Tentative Approval
  
|